.png){kind=icon}
.png){kind=icon}
Return
HER2-Mutant Non-Small Cell Lung Cancer Podcast: Knowledge Is Power
.png){kind=icon}
OA
AI
V
M
X
DOI：10.1007/s11523-026-01214-3.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
In the first episode of our podcast series, we introduce the emerging landscape of HER2-mutant non-small cell lung cancer (NSCLC), highlighting its place within the broader context of lung cancer. We explain what makes HER2-mutant NSCLC unique, from its epidemiology and biology to the molecular mechanisms driving cancer growth. We discuss the evolution of precision medicine in NSCLC, the role of HER2 as a therapeutic target, and how advances in molecular profiling have enabled the development of targeted therapies. The episode also covers the latest treatment strategies, including antibody–drug conjugates and tyrosine kinase inhibitors, and reviews the challenges and opportunities that define this aggressive cancer subtype. This podcast aims to enhance understanding of HER2-mutant NSCLC and the evolving therapeutic landscape that is reshaping management strategies for this aggressive disease.
Keywords:
HER2-mutant NSCLC
precision medicine
targeted therapy
antibody-drug conjugates
tyrosine kinase inhibitors
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
4
Papers:
1.2K
Citations:
2.5K
Organization
View more organizations